Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METGastric: Onartuzumab + mFOLFOX6 in MET+ GEC
NCT01662869Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2012
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of onartuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Roche. Started Nov 2012; status: completed.
02
Drugs
onartuzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01662869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01662869.